Article

Pharmacies Sell Scarce Drugs to Secondary Distributors: Report

Secondary drug distributors acquired about 70% of drugs in short supply from pharmacies, according to a Congressional report that tracked the pedigrees of 300 drugs (PDF) bought and sold on the gray market.

The report, released today during a Senate Committee on Commerce, Science and Transportation hearing, is part of the investigation into gray market activity that Rep. Elijah Cummings (D-Md.) launched last year.

Read the full story: http://tinyurl.com/c3uqfwb

Source: ModernHealthcare.com

Related Videos
ATS 2025
Bridgette J. Picou, LVN, ACLPN, The Well Project
John Barkett, MBA
1 expert in this video
Dr Gerard Criner
Emma Achola-Kothari, PhD
Dr Margrit Wiesendanger
Related Content
Throughout the study period, the number of DALYs associated with RA increased by 82.63%, rising across all age groups. | Image credit: Evrymmnt - stock.adobe.com
May 24th 2025

Increased Incidence but Lower Mortality From RA Seen Over Last 3 Decades

AJMC Contributor
The rate of rheumatoid arthritis (RA) has increased over the last 32 years, with certain groups of interest facing higher burden, finds a new analysis.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
The findings also show that ropeginterferon alfa-2b is an effective therapy for molecular response in early polycythemia vera. | Image credit: fotogurmespb.- stock.adobe.com
May 23rd 2025

Molecular Response to Therapy Linked With Event-Free Survival in PV

Jared Kaltwasser
New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Crohn's disease and guselkumab | Image credit: New Africa - stock.adobe.com
May 23rd 2025

Guselkumab Demonstrates Rapid and Lasting Results in Crohn Disease

Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a promising treatment alternative.
The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

Jared Kaltwasser
Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo